June 26, 2018
Video
Folate receptor alpha was a promising biomarker when it came to treatment with mirvetuximab soravtansine.
Commitment to Patients Is Driven by a Lasting Promise
Understanding the FDA Imfinzi Combo Approval for Bladder Cancer Care
New Options for ER+ Breast Cancer Spotlighted at Patient Event
A Digital Detox for the Soul with Lynch Syndrome